L 52/34
EN
Official Journal of the European Union
20.2.2023
ANNEX XI
African horse sickness (AHS) PART 1 SPECIFIC CONDITIONS FOR THE IMPLEMENTATION OF EMERGENCY PROTECTIVE VACCINATION FOR PREVENTION AND CONTROL OF AHS
1.
Type of vaccine to be used or prioritised: Monovalent vaccines or, if monovalent vaccines are not available, poly­ valent vaccines with the least possible number of valences authorised by the competent authority. 2.
Size of the vaccination zone: infected establishments subject to the derogation provided for in Annex III to Delegated Regulation (EU) 2020/687 and establishments located within a 20 km radius around the infected establishments (included in the protection zone).
A vaccination zone may cover the entire protection zone.
Any vaccination in the surveillance zone is prohibited. 3.
Size of the peri-vaccination zone: No specific conditions 4.
Minimum coverage: No specific conditions 5.
Targeted animals/species: all equine animals in the vaccination zone, in accordance with the instruction of the vaccine manufacturer/the marketing authorisation.
PART 2 SPECIFIC CONDITIONS FOR THE REINFORCED CLINICAL AND LABORATORY SURVEILLANCE TO BE IMPLEMENTED IN THE VACCINATION AND PERI-VACCINATION ZONES DURING EMERGENCY PROTECTIVE VACCINATION FOR PREVENTION AND CONTROL OF AHS
Clinical and laboratory surveillance shall be carried out in the vaccination zone.
This surveillance shall include at least: 1. a clinical examination of equine animals every 3 to 7 days, or each day in the case of severe clinical cases, since such cases may need to be euthanised because of animal welfare reasons; 2. a laboratory surveillance of equine animals (testing should be carried out on samples taken at intervals of 3 to 7 days as the minimum time required to capture the minimum incubation period after which an infected animal may test positive), and the diagnostic protocol shall be set up according to the vaccine used (a serological surveillance, in case a DIVA vaccine is used, or a virological surveillance).
The surveillance is necessary to detect the AHS virus types circulating to ensure that all circulating serotypes are included in the official vaccination plan; 3. a surveillance of Culicoides.
PART 3 SPECIFIC CONDITIONS FOR THE PROHIBITION OF MOVEMENTS OF ANIMALS AND PRODUCTS AND FOR GRANTING A DEROGATION IN ACCORDANCE WITH ARTICLE 13, IN A VACCINATION ZONE WHERE EMERGENCY PROTECTIVE VACCINATION FOR PREVENTION AND CONTROL OF AHS IS CARRIED OUT
1.
Animals and products subject to prohibition of movements Equine animals and germinal products thereof from the vaccination zone until the end of the recovery period. 2.
Germinal products subject to prohibition of collection: none.